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Abstract
We herein report a case of a 55-year-old female with an unusual case of post-operative kratom withdrawal. The patient’s
withdrawal symptoms subsequently contributed to complications and admission to the intensive care unit. Features of
this case are discussed, alongside the management of kratom withdrawal and the implications of supplementation with
unregulated herbal medications.

INTRODUCTION
Nearly 20% of adults in the USA used an herbal medicine
or supplement in the past year [1]. One specific herbal
medicine, kratom, has become increasingly popular within
the USA for its supposed alleviation of anxiety and chronic
pain [2]. We would like to report a patient whose postoperative course was prolonged secondary to withdrawal from
kratom.

CASE PRESENTATION
A 55-year-old female with a history of chronic back pain, anxiety
and depression was admitted to the hospital for an elective
subtotal colectomy and ileorectal anastomosis for colonic
inertia. On admission, her medications were documented:
acetaminophen/oxycodone (5/325 1 PO q6h prn), escitalopram
(10 mg 1 PO qd), cyclobenzaprine (10 mg 1 PO tid), bupropion
(100 mg 1 PO qd) and omeprazole (40 mg PO bid). The patient
admitted to drinking 1–2 drinks of alcohol weekly and denied
any history of drug abuse. The surgery was uneventful, and the
patient was started on home medications and a clear liquid

diet within 24 hours of the surgery. Intravenous hydromorphone
(1 dose—0.5 mg) and oral tramadol were used for pain control
within the first 48 hours following the operation.
On postoperative day 2, the patient became nauseous and
vomited approximately 500 cc of bilious liquid. Over the next
24 hours, the patient became confused, agitated and developed
auditory and visual hallucinations. She stated, ‘Men are talking to me from my IV and are trying to kill me’. Her physical examination and lab studies remained normal. Since drug
and/or alcohol withdrawal was suspected, the patient’s husband was contacted to review her medication and social history. After some prodding, the husband revealed that in addition to her prescribed medications, the patient, in an attempt
to alleviate her pain and anxiety, for many years, was taking an over-the-counter preparation called kratom (5–10 g, oral
daily).
On postoperative Day 4, the patient became febrile (40.1 ◦ C),
tachycardic (155 beats/min) and hypotensive (80 mm Hg/undetected). The abdominal exam remained unremarkable. The
patient was transferred to the ICU for presumed septic shock.
Diagnostic studies revealed right basal pulmonary infiltrates
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most consistent with aspiration pneumonia. The patient was
stabilized and started on IV antibiotics. She was transferred from
the ICU within 24 hours and subsequently discharged from the
hospital in good health on Day 12.

DISCUSSION
Mitragyna speciosa, commonly referred to as kratom, is a tropical
plant native to Southeast Asia, where it has been used as a form
of alternative medicine for anxiety and chronic pain since the
early nineteenth century [3]. At low doses (1–5 g), mitragynine,
the active compound in kratom, can provide the user with a
stimulant effect, and at high doses (5–15 g) act as a µ-opioid
agonist [4,5]. Adverse effects include agitation, constipation, dry
mouth and withdrawal symptoms such as nausea, vomiting and
psychosis [6]. Despite adverse effects and its association with 152
overdose deaths over the course of 2016 and 2017, kratom, or
similar compounds that include mitragynine, are readily available for online purchase [7]. There are no FDA-approved uses
for kratom, and the FDA has recently submitted warning letters
to distributors of kratom for illegally making claims about their
ability to treat or cure opioid addiction and withdrawal symptoms.
When our patient became nauseous and vomited, we initially
suspected that her symptoms were secondary to an ileus or
obstruction. Although an ileus may have contributed to the
patient’s emesis, our working diagnosis did not explain the
patient’s hallucinations. Our patient was given lorazepam (1 g,
IV push) for this episode of agitation, since the timing and
symptoms were congruent with alcohol or benzodiazepine withdrawal [8].
Once we ascertained that the patient was taking excessive
amounts of kratom, our management became supportive in the
form of haloperidol (5 mg, intramuscular) for agitation. Although
there have been anecdotal reports of kratom withdrawal management with buprenorphine, in the acute setting, standard
management is largely supportive in the form of IV hydration
and treatment of symptoms as they arise [9]. We were unable to
find any standard guidelines for treating kratom withdrawal.
If our patient had disclosed her kratom use, we might have
been able to have prevented the post-operative complications
by protecting the patient’s airway. Failure to report herbal
medicines and supplements is a serious issue in the healthcare
industry. One study reported that 42.7% of patients who consume
herbal medicines or supplements do not report their usage to
their healthcare providers [10]. Among those, 46% cited that it
was not necessary for their physician to know, while 57% claimed
that they were never asked [10].
Kratom is one of many over-the-counter herbal medicines
and supplements, which has been associated with serious,
potentially fatal adverse effects [1]. The Department of Health
and Human Services has recommended that it is classified as
a Schedule I Drug (equivalent to Heroin/LSD). Since producers
of these over-the-counter products are not required to provide
efficacy, safety or quality prior to marketing or post-marketing
adverse events to the FDA, the burden lies with physicians to
be well educated and determine, as part of taking a complete
history, if their patients are taking supplements and adjust
patient care accordingly [1].

Over-the-counter and herbal supplements, such as kratom,
can often be addictive and result in withdrawal effects, which
can complicate a post-operative course, leading to a prolonged
hospitalization and increased healthcare costs. Because of the
increasing popularity of kratom, physicians need to become
familiar with the pharmacology and potential adverse effects.
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